Taysha Gene Therapies is trading at $3.91, down 5.56%, with biotech-sector weakness a possible contributing factor. - No clear company-specific catalyst for the October 13 decline surfaced in the search. - The investor-relations page lists an October 1 release; the October 2 inducement grant is not a new October 13 development. Biotech was down 2.01%, but that does not establish the cause of this individual stock move.